Literature DB >> 16046113

Epidemiological survey on incidence and treatment of community acquired pneumonia in Italy.

Giovanni Viegi1, Riccardo Pistelli, Mario Cazzola, Franco Falcone, Isa Cerveri, Andrea Rossi, Giuseppe Ugo Di Maria.   

Abstract

STUDY
OBJECTIVES: To estimate annual incidence of community acquired pneumonia (CAP) in an Italian general population sample. DESIGN AND PARTICIPANTS: Two hundred and eighty-seven family practitioners (64.6% of those selected) recorded suspected or ascertained CAP cases for 1 year. Information on smoking habit, respiratory symptoms and signs, co-morbidity, antibiotic and corticosteroid therapy, hospitalization, mortality and recovery were obtained.
RESULTS: Six hundred and ninety-nine case forms were collected (53.1% females, mean age 59.6+/-19.5, 20.6% smokers). CAP incidence rates per 1000 population were: 1.69 in men vs. 1.71 in women; 2.33 in the North vs. 1.29 in the Centre-South of Italy; between 0.73 in 14-, and 3.34 in 64+year-old subjects. Main symptoms and signs were cough (73.3%), crackles (72.8%), dullness (57.3%), asthenia (53.4%). 59.5% of subjects had concurrent diseases, mostly cardiac and respiratory. 77.2% of cases had chest X-ray (with parenchymal density in 90.6%). Phlegm microbiological examination was performed in 12.8% of cases. First choice antibiotics were cephalosporins (45.8%), macrolides (20.2%), other beta-lactams (18.6%), and fluoroquinolones (12.2%). Rates of hospitalization and of mortality were 31.8% and 6.0%, respectively.
CONCLUSION: This study confirmed that the annual CAP incidence rate in the general population of South Europe is about 2 per 1000 population and showed a wide choice of antibiotic treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16046113     DOI: 10.1016/j.rmed.2005.04.013

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  15 in total

1.  The multidimensional prognostic index predicts short- and long-term mortality in hospitalized geriatric patients with pneumonia.

Authors:  Alberto Pilotto; Filomena Addante; Luigi Ferrucci; Gioacchino Leandro; Grazia D'Onofrio; Michele Corritore; Valeria Niro; Carlo Scarcelli; Bruno Dallapiccola; Marilisa Franceschi
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2009-04-06       Impact factor: 6.053

2.  Economic studies applied to vaccines against invasive diseases: An updated budget impact analysis of age-based pneumococcal vaccination strategies in the elderly in Italy.

Authors:  Sara Boccalini; Angela Bechini; Roberto Gasparini; Donatella Panatto; Daniela Amicizia; Paolo Bonanni
Journal:  Hum Vaccin Immunother       Date:  2016-12-07       Impact factor: 3.452

3.  Cost-effectiveness of new adult pneumococcal vaccination strategies in Italy.

Authors:  Sara Boccalini; Angela Bechini; Miriam Levi; Emila Tiscione; Roberto Gasparini; Paolo Bonanni
Journal:  Hum Vaccin Immunother       Date:  2013-01-07       Impact factor: 3.452

Review 4.  Risk factors and severity scores in hospitalized patients with community-acquired pneumonia: prediction of severity and mortality.

Authors:  T Welte
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-05-01       Impact factor: 3.267

5.  A retrospective analysis of hospital discharge records for S. pneumoniae diseases in the elderly population of Florence, Italy, 2010-2012.

Authors:  Angela Bechini; Cristina Taddei; Alessandro Barchielli; Miriam Levi; Emilia Tiscione; Maria Grazia Santini; Fabrizio Niccolini; Maria Teresa Mechi; Donatella Panatto; Daniela Amicizia; Chiara Azzari; Paolo Bonanni; Sara Boccalini
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

6.  Guidelines for diagnosis and management of community- and hospital-acquired pneumonia in adults: Joint ICS/NCCP(I) recommendations.

Authors:  Dheeraj Gupta; Ritesh Agarwal; Ashutosh Nath Aggarwal; Navneet Singh; Narayan Mishra; G C Khilnani; J K Samaria; S N Gaur; S K Jindal
Journal:  Lung India       Date:  2012-07

7.  Community-acquired pneumonia: aetiologic changes in a limited geographic area. An 11-year prospective study.

Authors:  R Fernández Alvarez; I Suárez Toste; G Rubinos Cuadrado; A Torres Lana; J A Gullón Blanco; A Jiménez; I González Martín
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-07       Impact factor: 5.103

8.  Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy.

Authors:  Ayman M Noreddin; Walid F Elkhatib; Kenji M Cunnion; George G Zhanel
Journal:  Drug Healthc Patient Saf       Date:  2011-10-07

9.  Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia.

Authors:  Cristina Tanaseanu; Slobodan Milutinovic; Petre I Calistru; Janos Strausz; Marius Zolubas; Valeriy Chernyak; Nathalie Dartois; Nathalie Castaing; Hassan Gandjini; C Angel Cooper
Journal:  BMC Pulm Med       Date:  2009-09-09       Impact factor: 3.317

10.  The burden of community-acquired pneumonia in the elderly: the Spanish EVAN-65 study.

Authors:  Olga Ochoa-Gondar; Angel Vila-Córcoles; Cinta de Diego; Victoria Arija; Monica Maxenchs; Montserrat Grive; Enrique Martin; Josep L Pinyol
Journal:  BMC Public Health       Date:  2008-06-27       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.